Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways
Acta Haematologica · 2024
DOI: 10.1159/000534101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Mu-Nan Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Naphthoquinones, Leukemia, Myeloid, Acute, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Acute myeloid leukemia (AML) with internal tandem duplication (ITD) mutations in Fms-like tyrosine kinase 3 (FLT3) has an unfavorable prognosis. Recently, using newly emerging inhibitors of FLT3 has led to improved outcomes of patients with FLT3-ITD mutations. However, drug resistance and relapse continue to be significant challenges in the treatment of patients with FLT3-ITD mutations. This study aimed to evaluate the antileukemic effects of shikonin (SHK) and its mechanisms of action against AML cells with FLT3-ITD mutations in vitro and in vivo.
Methods
The CCK-8 assay was used to analyze cell viability, and flow cytometry was used to detect cell apoptosis and differentiation. Western blotting and real-time polymerase chain reaction were used to examine the expression of certain proteins and genes. Leukemia mouse model was created to evaluate the antileukemia effect of SHK against FLT3-ITD mutated leukemia in vivo.
Results
After screening a series of leukemia cell lines, those with FLT3-ITD mutations were found to be more sensitive to SHK in terms of proliferation inhibition and apoptosis induction than those without FLT3-ITD mutation. SHK suppresses the expression and phosphorylation of FLT3 receptors and their downstream molecules. Inhibition of the NF-κB/miR-155 pathway is an important mechanism through which SHK kills FLT3-AML cells. Moreover, a low concentration of SHK promotes the differentiation of AML cells with FLT3-ITD mutations. Finally, SHK could significantly inhibit the growth of MV4-11 cells in leukemia bearing mice.
Conclusion
The findings of this study indicate that SHK may be a promising drug for the treatment of FLT3-ITD mutated AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer, The First Hospital of Jilin University, Changchun, China.
- Department of Hematology, The First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Zhao, M. N., Su, L., Song, F., Wei, Z. F., Qin, T. X., Zhang, Y. W., Li, W., & Gao, S. J. (2024). Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways. Acta Haematologica. https://doi.org/10.1159/000534101
Vancouver
Zhao MN, Su L, Song F, Wei ZF, Qin TX, Zhang YW, et al. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways. Acta Haematologica. 2024. doi:10.1159/000534101
BibTeX
@article{Zhao2024,
author = {Zhao, Mu-Nan and Su, Long and Song, Fei and Wei, Zhi-Feng and Qin, Tian-Xue and Zhang, Yun-Wei and Li, Wei and Gao, Su-Jun},
title = {Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000534101}
}
EUVIMED